Future work in the field should concentrate on creating seamless integration of AI systems with current endoscopy platforms and electronic medical records, developing training modules to teach clinicians how to use AI tools, and determining the best means for regulation and approval of new AI technology.Īrtificial intelligence (AI) has transformed information technology by unlocking large-scale, data-driven solutions to what once were time intensive problems. AI has also been utilized to identify gastrointestinal bleeding, to detect areas of inflammation, and even to diagnose certain gastrointestinal infections. The most promising of these efforts have been in computer-aided detection and computer-aided diagnosis of colorectal polyps, with recent systems demonstrating high sensitivity and accuracy even when compared to expert human endoscopists. Applications of artificial intelligence techniques, specifically machine learning and more recently deep learning, are beginning to emerge in gastrointestinal endoscopy. In recent years, researchers have harnessed artificial intelligence to analyze large-volume, unstructured medical data and perform clinical tasks, such as the identification of diabetic retinopathy or the diagnosis of cutaneous malignancies. The index is tracked by the iShares Biotechnology Index ( IBB ).Artificial intelligence (AI) enables machines to provide unparalleled value in a myriad of industries and applications. The top ten holdings have a 48.69% allocation. In addition, companies that are engaged in the production of tools or systems that enable biotechnology processes are included. The index was launched in 2012 and includes companies that are engaged in the research and development of therapeutic treatments but are not focused on the commercialization and mass production of pharmaceutical drugs. The ICE Biotechnology Index is a rules-based, modified float-adjusted market capitalization-weighted index that tracks the performance of qualifying U.S. The index is tracked by the First Trust NYSE Arca Biotechnology Index ( FBT ). The index is designed to reflect the performance of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. It constitutes the top 30 large-cap biotech companies and weights them equally. Next in line is the NYSE Arca Biotechnology Index.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |